<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39407954</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Innovative COVID-19 Point-of-Care Diagnostics Suitable for Tuberculosis Diagnosis: A Scoping Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5894</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13195894</ELocationID><Abstract><AbstractText>Rapid and accurate point-of-care (POC) tuberculosis (TB) diagnostics are crucial to bridge the TB diagnostic gap. Leveraging recent advancements in COVID-19 diagnostics, we explored adapting commercially available POC SARS-CoV-2 tests for TB diagnosis in line with the World Health Organization (WHO) target product profiles (TPPs). A scoping review was conducted following PRISMA-ScR guidelines to systematically map POC antigen and molecular SARS-CoV-2 diagnostic tests potentially meeting the TPPs for TB diagnostic tests for peripheral settings. Data were gathered from PubMed/MEDLINE, bioRxiv, medRxiv, publicly accessible in vitro diagnostic test databases, and developer websites up to 23 November 2022. Data on developer attributes, operational characteristics, pricing, clinical performance, and regulatory status were charted using standardized data extraction forms and evaluated with a standardized scorecard. A narrative synthesis of the data is presented. Our search yielded 2003 reports, with 408 meeting eligibility criteria. Among these, we identified 66 commercialized devices: 22 near-POC antigen tests, 1 POC molecular test, 31 near-POC molecular tests, and 12 low-complexity molecular tests potentially adaptable for TB. The highest-scoring SARS-CoV-2 diagnostic tests were the near-POC antigen platform LumiraDx (Roche, Basel, Switzerland), the POC molecular test Lucira Check-It (Pfizer, New York, NY, USA), the near-POC molecular test Visby (Visby, San Jose, CA, USA), and the low-complexity molecular platform Idylla (Biocartis, Lausanne, Switzerland). We highlight a diverse landscape of commercially available diagnostic tests suitable for potential adaptation to peripheral TB testing. This work aims to bolster global TB initiatives by fostering stakeholder collaboration, leveraging SARS-CoV-2 diagnostic technologies for TB, and uncovering new commercial avenues to tackle longstanding challenges in TB diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holtgrewe</LastName><ForeName>Lydia M L</ForeName><Initials>LML</Initials><Identifier Source="ORCID">0000-0003-3692-0469</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Sonal</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3252-1727</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekova</LastName><ForeName>Ralitza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broger</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0001-3443-358X</Identifier><AffiliationInfo><Affiliation>Connected Diagnostics Limited, London WC2H 9JQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theron</LastName><ForeName>Grant</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9216-2415</Identifier><AffiliationInfo><Affiliation>DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, P.O. Box 241, Cape Town 8000, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahid</LastName><ForeName>Payam</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2811-1311</Identifier><AffiliationInfo><Affiliation>UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattamanchi</LastName><ForeName>Adithya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pulmonary Diseases and Critical Medicine, University of California Irvine, Irvine, CA 92697, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denkinger</LastName><ForeName>Claudia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Heidelberg University Hospital, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerlikaya</LastName><ForeName>Seda</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6064-548X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and Tropical Medicine, Heidelberg University Hospital and Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Heidelberg University Hospital, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AI152087</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AI152087</GrantID><Agency>National Institute of Allergy and Infectious Diseases of the National Institutes of Health</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Jun 13:2024.06.13.24308880. doi: 10.1101/2024.06.13.24308880</RefSource><PMID Version="1">38947060</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">missed diagnosis</Keyword><Keyword MajorTopicYN="N">point-of-care testing</Keyword><Keyword MajorTopicYN="N">rapid diagnostic tests</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword></KeywordList><CoiStatement>Authors declare no financial conflicts of interest. T.B. holds patents in the fields of lipoarabinomannan detection and aerosol collection and is a shareholder of Avelo Ltd., a Swiss diagnostics company. C.I. is the owner of the commercial company Connected Diagnostics Limited. The company is incorporated in England with registration number 9445856. The company has worked for companies that sell medical devices and provides consultancy services to them. G.T.â€™s institution has received funding and in-kind consumables from LumiraDx for COVID-19 and TB research. C.M.D. has received or is expecting to receive research grants from the US National Institutes of Health (GN: 1U01AI152087-01), German Ministry of Education and Research (GN: 031L0298C; 01KX2121, 01KA2203A,), United States Agency for International Development (GN: 7200AA22CA00005), FIND, German Center for Infection Research and Global Health Innovative Technology Fund (GN: 8029802812, 8029802813, 8029802911, 8029802913, 8029903901, 8029903902) and WHO (GN: 2024/1440209-0, 2022/1253133-0, 2022/1237646-0). This includes grants to work with diagnostics developers. CMD never received funding from diagnostic developers except for a payment from Roche Diagnostics that she accepted as German law requires a manufacturer to pay for the use of data for regulatory purposes. The data was generated as part of an evaluation independent of Roche by CMD and team. CMD is an academic editor of PLoS Medicine and sits on the WHO technical advisory group on tuberculosis diagnostics. S.Y. is a member of the consultant staff of the R2D2 network.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407954</ArticleId><ArticleId IdType="pmc">PMC11477317</ArticleId><ArticleId IdType="doi">10.3390/jcm13195894</ArticleId><ArticleId IdType="pii">jcm13195894</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PAHO  Tuberculosis Response Recovering from Pandemic But Accelerated Efforts Needed to Meet New Targets. 2023.  [(accessed on 30 September 2024)].  Available online:  https://www.paho.org/en/news/7-11-2023-tuberculosis-response-recovering-pandemic-accelerated-efforts-needed-meet-new#:~:text=7%20November%202023%20(PAHO)%2D,19%20disruptions%20on%20TB%20services.</Citation></Reference><Reference><Citation>Sachdeva K.S., Kumar N. Closing the gaps in tuberculosis detection-considerations for policy makers. Lancet Glob. Health. 2023;11:e185â€“e186. doi: 10.1016/S2214-109X(23)00008-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(23)00008-6</ArticleId><ArticleId IdType="pubmed">36669799</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai M., Dewan P.K., Swaminathan S. Transforming tuberculosis diagnosis. Nat. Microbiol. 2023;8:756â€“759. doi: 10.1038/s41564-023-01365-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-023-01365-3</ArticleId><ArticleId IdType="pubmed">37127703</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . WHO Standard: Universal Access to Rapid Tuberculosis Diagnostics. WHO; Geneva, Switzerland: 2023.</Citation></Reference><Reference><Citation>Ismail N., Nathanson C.M., Zignol M., Kasaeva T. Achieving universal access to rapid tuberculosis diagnostics. BMJ Glob. Health. 2023;8:e012666. doi: 10.1136/bmjgh-2023-012666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2023-012666</ArticleId><ArticleId IdType="pmc">PMC10230866</ArticleId><ArticleId IdType="pubmed">37230547</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Global Tuberculosis Report. WHO; Geneva, Switzerland: 2023.</Citation></Reference><Reference><Citation>Subbaraman R., Jhaveri T., Nathavitharana R.R. Closing gaps in the tuberculosis care cascade: An action-oriented research agenda. J. Clin. Tuberc. Other Mycobact. Dis. 2020;19:100144. doi: 10.1016/j.jctube.2020.100144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jctube.2020.100144</ArticleId><ArticleId IdType="pmc">PMC7015982</ArticleId><ArticleId IdType="pubmed">32072022</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . WHO High-Priority Target Product Profiles for New Tuberculosis Diagnostics. WHO; Geneva, Switzerland: 2014.</Citation></Reference><Reference><Citation>WHO . Target Product Profile for Tuberculosis Diagnosis and Detection of Drug Resistance. WHO; Geneva, Switzerland: 2024.</Citation></Reference><Reference><Citation>Yerlikaya S., Broger T., Isaacs C., Bell D., Holtgrewe L., Gupta-Wright A., Nahid P., Cattamanchi A., Denkinger C.M. Blazing the trail for innovative tuberculosis diagnostics. Infection. 2024;52:29â€“42. doi: 10.1007/s15010-023-02135-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02135-3</ArticleId><ArticleId IdType="pmc">PMC10811035</ArticleId><ArticleId IdType="pubmed">38032537</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra K.K., Singh S. Tuberculosis: Newer diagnostic tests: Applications and limitations. Indian J. Tuberc. 2020;67:S86â€“S90. doi: 10.1016/j.ijtb.2020.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2020.09.025</ArticleId><ArticleId IdType="pubmed">33308677</ArticleId></ArticleIdList></Reference><Reference><Citation>Research TM. 2023.  [(accessed on 15 June 2024)].  Available online:  https://www.who.int/publications/i/item/9789240083851.</Citation></Reference><Reference><Citation>Research G.V. COVID-19 Diagnostics Market Size, Share &amp; Trends Analysis Report by Product &amp; Service (Instruments, Reagents &amp; Kits, Services), by Sample Type, by Test Type, by Mode, by End Use, by Region, and Segment Forecasts, 2022â€“2030. 2024.  [(accessed on 15 June 2024)].  Available online:  https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market.</Citation></Reference><Reference><Citation>Cioboata R., Biciusca V., Olteanu M., Vasile C.M. COVID-19 and Tuberculosis: Unveiling the Dual Threat and Shared Solutions Perspective. J. Clin. Med. 2023;12:4784. doi: 10.3390/jcm12144784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12144784</ArticleId><ArticleId IdType="pmc">PMC10381217</ArticleId><ArticleId IdType="pubmed">37510899</ArticleId></ArticleIdList></Reference><Reference><Citation>Levac D., Colquhoun H., Oâ€™Brien K.K. Scoping studies: Advancing the methodology. Implement. Sci. 2010;5:69. doi: 10.1186/1748-5908-5-69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-5908-5-69</ArticleId><ArticleId IdType="pmc">PMC2954944</ArticleId><ArticleId IdType="pubmed">20854677</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco A.C., Lillie E., Zarin W., Oâ€™Brien K.K., Colquhoun H., Levac D., Moher D., Peters M.D.J., Horsley T., Weeks L., et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann. Intern. Med. 2018;169:467â€“473. doi: 10.7326/M18-0850.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-0850</ArticleId><ArticleId IdType="pubmed">30178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerlikaya S., Holtgrewe L.M., Broger T., Isaacs C., Nahid P., Cattamanchi A., Denkinger C.M. Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: A scoping review protocol. BMJ Open. 2023;13:e065194. doi: 10.1136/bmjopen-2022-065194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-065194</ArticleId><ArticleId IdType="pmc">PMC9922875</ArticleId><ArticleId IdType="pubmed">36754560</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Public Consultation for the Target Product Profile TB Diagnostic Tests for Peripheral Settings: WHO; 2023.  [(accessed on 15 June 2024)].  Available online:  https://www.who.int/news-room/articles-detail/public-consultation-for-the-target-product-profile-tb-diagnostic-tests-for-peripheral-settings.</Citation></Reference><Reference><Citation>Daily C. National Medicial Products Administration Database Beijing.  [(accessed on 24 June 2024)];2024  Available online:  https://www.nmpa.gov.cn/datasearch/en/search-result-en.html?nmpaItem=%2082808081889a0b5601889a251e33005c.</Citation></Reference><Reference><Citation>India Go. Central Drugs Standard Control Organization New Delhi.  [(accessed on 24 June 2024)];2024  Available online:  https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/InVitro-Diagnostics/</Citation></Reference><Reference><Citation>Commission E. EUDAMED-European Database on Medical Devices: European Commission. 2021.  [(accessed on 17 June 2024)].  Available online:  https://ec.europa.eu/tools/eudamed/#/screen/home.</Citation></Reference><Reference><Citation>Innovation VH. Covidence [Computer Software] Melbourne, Australia, 2024.  [(accessed on 30 September 2024)].  Available online:  https://www.covidence.org/</Citation></Reference><Reference><Citation>Lehe J.D., Sitoe N.E., Tobaiwa O., Loquiha O., Quevedo J.I., Peter T.F., Jani I.V. Evaluating operational specifications of point-of-care diagnostic tests: A standardized scorecard. PLoS ONE. 2012;7:e47459. doi: 10.1371/journal.pone.0047459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0047459</ArticleId><ArticleId IdType="pmc">PMC3485252</ArticleId><ArticleId IdType="pubmed">23118871</ArticleId></ArticleIdList></Reference><Reference><Citation>360Dx. Roche to Acquire LumiraDx Point-of-Care Testing Tech for Up to $350M. 2024.  [(accessed on 5 April 2024)].  Available online:  https://www.360dx.com/business-news/roche-acquire-lumiradx-point-care-testing-tech-350m?CSAuthResp=1712329219737%3A0%3A2731195%3A1911%3A24%3Asuccess%3AF7A508B010CAA6F6BDBA33CDA751578C&amp;_ga=2.119195471.790131286.1712329165-1006766003.1711110768&amp;adobe_mc=MCMID%3D26734529761092225790874085618419779486%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1712329173.</Citation></Reference><Reference><Citation>Twabi H.H. TB Diagnostics: Existing Platform and Future Direction. Am. J. Biomed. Sci. Res. 2022;15 doi: 10.34297/AJBSR.2022.15.002169.</Citation><ArticleIdList><ArticleId IdType="doi">10.34297/AJBSR.2022.15.002169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger L.J., Klein J.A.F., Tobian F., Gaeddert M., Lainati F., Klemm S., Schnitzler P., Bartenschlager R., Cerikan B., Neufeldt C.J., et al. Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx: An antigen-detecting point-of-care device for SARS-CoV-2. Infection. 2022;50:395â€“406. doi: 10.1007/s15010-021-01681-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01681-y</ArticleId><ArticleId IdType="pmc">PMC8358901</ArticleId><ArticleId IdType="pubmed">34383260</ArticleId></ArticleIdList></Reference><Reference><Citation>Broger T., Nicol M.P., Sigal G.B., Gotuzzo E., Zimmer A.J., Surtie S., Caceres-Nakiche T., Mantsoki A., Reipold E.I., SzÃ©kely R., et al. Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients. J. Clin. Investig. 2020;130:5756â€“5764. doi: 10.1172/JCI140461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140461</ArticleId><ArticleId IdType="pmc">PMC7598043</ArticleId><ArticleId IdType="pubmed">32692731</ArticleId></ArticleIdList></Reference><Reference><Citation>Broger T., Tsionksy M., Mathew A., Lowary T.L., Pinter A., Plisova T., Bartlett D., Barbero S., Denkinger C.M., Moreau E., et al. Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients. PLoS ONE. 2019;14:e0215443. doi: 10.1371/journal.pone.0215443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0215443</ArticleId><ArticleId IdType="pmc">PMC6472883</ArticleId><ArticleId IdType="pubmed">30998715</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulterys M.A., Wagner B.G., Redard-Jacot Ml Suresh A., Pollock N.R., Moreau E., Denkinger C.M., Drain P.K., Broger T. Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update. J. Clin. Med. 2019;9:111. doi: 10.3390/jcm9010111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010111</ArticleId><ArticleId IdType="pmc">PMC7020089</ArticleId><ArticleId IdType="pubmed">31906163</ArticleId></ArticleIdList></Reference><Reference><Citation>Denkinger C.M., Nicolau I., Ramsay A., Chedore P., Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur. Respir. J. 2013;42:544â€“547. doi: 10.1183/09031936.00081113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00081113</ArticleId><ArticleId IdType="pubmed">23904551</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre E., Isaacs C., Affolabi D., Alagna R., Brockmann D., de Jong B.C., Cambau E., Churchyard G., Cohen T., Delmee M., et al. Connectivity of diagnostic technologies: Improving surveillance and accelerating tuberculosis elimination. Int. J. Tuberc. Lung Dis. 2016;20:999â€“1003. doi: 10.5588/ijtld.16.0015.</Citation><ArticleIdList><ArticleId IdType="doi">10.5588/ijtld.16.0015</ArticleId><ArticleId IdType="pmc">PMC4937753</ArticleId><ArticleId IdType="pubmed">27393530</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell D., Gaffga N.H., Weinstock H., Peterman T.A. Integration of Surveillance for STDs, HIV, Hepatitis, and TB: A Survey of U.S. STD Control Programs. Public Health Rep. 2009;124((Suppl. 2)):31â€“38. doi: 10.1177/00333549091240S206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00333549091240S206</ArticleId><ArticleId IdType="pmc">PMC2775398</ArticleId><ArticleId IdType="pubmed">27382652</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO Releases New List of Essential Diagnostics; New Recommendations for Hepatitis E Virus Tests, Personal Use Glucose Meters. WHO: Geneva, Switzerland, 2023.  [(accessed on 14 March 2024)].  Available online:  https://www.who.int/news/item/19-10-2023-who-releases-new-list-of-essential-diagnostics--new-recommendations-for-hepatitis-e-virus-tests--personal-use-glucose-meters.</Citation></Reference><Reference><Citation>FIND . Diagnostic Network Optimization. FIND; Geneva, Switzerland: 2024.</Citation></Reference><Reference><Citation>Girdwood S., Pandey M., Machila T., Warrier R., Gautam J., Mukumbwa-Mwenechanya M., Benade M., Nichols K., Shibemba L., Mwewa J., et al. The integration of tuberculosis and HIV testing on GeneXpert can substantially improve access and same-day diagnosis and benefit tuberculosis programmes: A diagnostic network optimization analysis in Zambia. PLOS Glob. Public Health. 2023;3:e0001179. doi: 10.1371/journal.pgph.0001179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0001179</ArticleId><ArticleId IdType="pmc">PMC10022337</ArticleId><ArticleId IdType="pubmed">36963019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ntinginya N.E., Kuchaka D., Orina F., Mwebaza I., Liyoyo A., Miheso B., Aturinde A., Njeleka F., Kiula K., Msoka E.F., et al. Unlocking the health system barriers to maximise the uptake and utilisation of molecular diagnostics in low-income and middle-income country setting. BMJ Glob. Health. 2021;6:e005357. doi: 10.1136/bmjgh-2021-005357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005357</ArticleId><ArticleId IdType="pmc">PMC8386239</ArticleId><ArticleId IdType="pubmed">34429298</ArticleId></ArticleIdList></Reference><Reference><Citation>Steadman A., Andama A., Ball A., Mukwatamundu J., Khimani K., Mochizuki T., Asege L., Bukirwa A., Kato J.B., Katumba D., et al. New manual qPCR assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular TB diagnostics. Clin. Infect. Dis. 2024;78:1313â€“1320. doi: 10.1093/cid/ciae041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae041</ArticleId><ArticleId IdType="pmc">PMC11093664</ArticleId><ArticleId IdType="pubmed">38306491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesman A.W., Rodriguez C., Ager E., Coit J., Trevisi L., Franke M.F. Diagnostic accuracy of molecular detection of Mycobacterium tuberculosis in pediatric stool samples: A systematic review and meta-analysis. Tuberculosis. 2019;119:101878. doi: 10.1016/j.tube.2019.101878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tube.2019.101878</ArticleId><ArticleId IdType="pmc">PMC6914260</ArticleId><ArticleId IdType="pubmed">31670064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassane-Harouna S., Braet S.M., Decroo T., Camara L.M., Delamou A., Bock S., OrtuÃ±o-GutiÃ©rrez N., Cherif G.-F., Williams C.M., Wisniewska A., et al. Face mask sampling (FMS) for tuberculosis shows lower diagnostic sensitivity than sputum sampling in Guinea. Ann. Clin. Microbiol. Antimicrob. 2023;22:81. doi: 10.1186/s12941-023-00633-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-023-00633-8</ArticleId><ArticleId IdType="pmc">PMC10486030</ArticleId><ArticleId IdType="pubmed">37679838</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiano F., Jones S.E.I., Amin-Chowdhury Z., Flood J., Okike I., Brent A., Brent B., Beckmann J., Garstang J., Ahmad S., et al. Feasibility and acceptability of SARS-CoV-2 testing and surveillance in primary school children in England: Prospective, cross-sectional study. PLoS ONE. 2021;16:e0255517. doi: 10.1371/journal.pone.0255517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255517</ArticleId><ArticleId IdType="pmc">PMC8396768</ArticleId><ArticleId IdType="pubmed">34449784</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels B., Kwan A., Pai M., Das J. Lessons on the quality of tuberculosis diagnosis from standardized patients in China, India, Kenya, and South Africa. J. Clin. Tuberc. Other Mycobact. Dis. 2019;16:100109. doi: 10.1016/j.jctube.2019.100109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jctube.2019.100109</ArticleId><ArticleId IdType="pmc">PMC6830154</ArticleId><ArticleId IdType="pubmed">31720433</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooy A., Ockhuisen T., Korobitsyn A., Khan S.A., Ruhwald M., Ismail N., Kohli M., Nichols B.E. Trade-offs between clinical performance and test accessibility in tuberculosis diagnosis: A multi-country modelling approach for target product profile development. Lancet Glob. Health. 2024;12:e1139â€“e1148. doi: 10.1016/S2214-109X(24)00178-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(24)00178-5</ArticleId><ArticleId IdType="pubmed">38876761</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams C.M., Abdulwhhab M., Birring S.S., De Kock E., Garton N.J., Townsend E., Pareek M., Al-Taie A., Pan J., Ganatra R., et al. Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: Prospective observational studies. Lancet Infect. Dis. 2020;20:607â€“617. doi: 10.1016/S1473-3099(19)30707-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30707-8</ArticleId><ArticleId IdType="pmc">PMC7191268</ArticleId><ArticleId IdType="pubmed">32085847</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams C.M., Cheah E.S., Malkin J., Patel H., Otu J., Mlaga K., Sutherland J.S., Antonio M., Perera N., Woltmann G., et al. Face mask sampling for the detection of Mycobacterium tuberculosis in expelled aerosols. PLoS ONE. 2014;9:e104921. doi: 10.1371/journal.pone.0104921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104921</ArticleId><ArticleId IdType="pmc">PMC4133242</ArticleId><ArticleId IdType="pubmed">25122163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson T.M., Weigel K.M., Lakey Becker A., Ontengco D., Narita M., Tolstorukov I., Doebler R., Cangelosi G.A., Niemz A. Pilot study of a rapid and minimally instrumented sputum sample preparation method for molecular diagnosis of tuberculosis. Sci. Rep. 2016;6:19541. doi: 10.1038/srep19541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep19541</ArticleId><ArticleId IdType="pmc">PMC4726292</ArticleId><ArticleId IdType="pubmed">26785769</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandeventer P.E., Weigel K.M., Salazar J., Erwin B., Irvine B., Doebler R., Nadim A., Cangelosi G.A., Niemz A. Mechanical disruption of lysis-resistant bacterial cells by use of a miniature, low-power, disposable device. J. Clin. Microbiol. 2011;49:2533â€“2539. doi: 10.1128/JCM.02171-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02171-10</ArticleId><ArticleId IdType="pmc">PMC3147885</ArticleId><ArticleId IdType="pubmed">21543569</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA  Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Test for Self-Testing at Home.  [(accessed on 18 September 2024)];2020  Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home.</Citation></Reference><Reference><Citation>FDA  FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process.  [(accessed on 28 June 2024)];2024  Available online:  https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-covid-19-home-test-using-traditional-premarket-review-process.</Citation></Reference><Reference><Citation>Jaroenram W., Kampeera J., Arunrut N., Sirithammajak S., Jaitrong S., Boonnak K., Khumwan P., Prammananan T., Chaiprasert A., Kiatpathomchai W. Ultrasensitive detection of Mycobacterium tuberculosis by a rapid and specific probe-triggered one-step, simultaneous DNA hybridization and isothermal amplification combined with a lateral flow dipstick. Sci. Rep. 2020;10:16976. doi: 10.1038/s41598-020-73981-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73981-6</ArticleId><ArticleId IdType="pmc">PMC7550604</ArticleId><ArticleId IdType="pubmed">33046776</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugakani R.K., Bonam W., Erickson D., Mehta S. An isothermal amplification-based point-of-care diagnostic platform for the detection of Mycobacterium tuberculosis: A proof-of-concept study. Curr. Res. Biotechnol. 2021;3:154â€“159. doi: 10.1016/j.crbiot.2021.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crbiot.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8301208</ArticleId><ArticleId IdType="pubmed">34308334</ArticleId></ArticleIdList></Reference><Reference><Citation>FIND  Accessible Pricing: FIND. 2024.  [(accessed on 15 March 2024)].  Available online:  https://www.finddx.org/what-we-do/cross-cutting-workstreams/market-innovations/accessible-pricing/</Citation></Reference><Reference><Citation>Hannay E., Pai M. Breaking the cycle of neglect: Building on momentum from COVID-19 to drive access to diagnostic testing. EClinicalMedicine. 2023;57:101867. doi: 10.1016/j.eclinm.2023.101867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101867</ArticleId><ArticleId IdType="pmc">PMC9933317</ArticleId><ArticleId IdType="pubmed">36820097</ArticleId></ArticleIdList></Reference><Reference><Citation>360Dx. WHO, Medicines Patent Pool License Rapid Diagnostics Technology From SD Biosensor: 360Dx; 2024.  [(accessed on 22 March 2024)].  Available online:  https://www.360dx.com/business-news/who-medicines-patent-pool-license-rapid-diagnostics-technology-sd-biosensor?adobe_mc=MCMID%3D19782619068757078863840638341405804837%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1706883764&amp;CSAuthResp=1%3A%3A2548842%3A273%3A24%3Asuccess%3A33042812B2DBBA2FDB7574A1C2C8E150.</Citation></Reference><Reference><Citation>Bigio J., MacLean E.L., Das R., Sulis G., Kohli M., Berhane S., Dinnes J., Deeks J.J., BrÃ¼mmer L.E., Denkinger C.M., et al. Accuracy of package inserts of SARS-CoV-2 rapid antigen tests: A secondary analysis of manufacturer versus systematic review data. Lancet Microbe. 2023;4:e875â€“e882. doi: 10.1016/S2666-5247(23)00222-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00222-7</ArticleId><ArticleId IdType="pubmed">37844595</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaout R., Lee R.A., Lee G.R., Callahan C., Yen C.F., Smith K.P., Arora R., Kirby J.E. SARS-CoV2 Testing: The Limit of Detection Matters. bioRxiv. 2020 doi: 10.1101/2020.06.02.131144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.06.02.131144</ArticleId><ArticleId IdType="pmc">PMC7929140</ArticleId><ArticleId IdType="pubmed">33532847</ArticleId></ArticleIdList></Reference><Reference><Citation>Trang B. Cue Health, COVID-19 Testing Company, Is Shutting Down: STAT; 2024.  [(accessed on 11 June 2024)].  Available online:  https://www.statnews.com/2024/05/22/cue-health-covid-19-test-maker-layoffs/#:~:text=In%20an%20abrupt%20change,as%20of%20Friday%2C%20May%2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>